CeaproTSXV: CZO

Ceapro to present at BioFinance conference

· Issued by Ceapro via CNW
EDMONTON, May 16 /CNW/ - Ceapro Inc. (TSX-V: CZO) today announced that
Dr. Mark Redmond will be presenting at the BioFinance 2005 conference to be
held in Toronto, Ontario, May 17- 19, 2005. The conference features
approximately 100 life sciences companies from Canada, United States, and
Europe. Ceapro's presentation will take place at 4:00 p.m. EDT on Wednesday,
May 18th; a copy of the slides will be posted on the Ceapro website.
"This is an important opportunity to introduce Ceapro to a wider
financial audience and generate greater exposure in the context of
biotechnology investments," said Dr. Mark Redmond, Ceapro's President and CEO.
"Our presentation will feature CeaProve(TM) as a new and important innovation
in the field of diabetes diagnostics and Ceapro's ability to deliver products
to market successfully, as demonstrated by our active ingredients and
veterinary therapeutic products business."
BioFinance 2005 (www.biofinance.ca) is the Life Science industry's
leading investor conference. The meeting brings together key players to
consider investment opportunities and issues affecting companies in
biotechnology, medical devices, diagnostics and research tools. Participants
include senior life science executives, institutional and venture capital
investors, industry analysts, corporate finance executives, and experts from
the scientific and medical communities in Canada, the United States, Europe,
and Asia.

2004 Annual and Special Meeting

Ceapro's annual and special meeting of shareholders will be held in
Edmonton, Alberta on Wednesday, June 1, 2005, at Lister Centre, University of
Alberta, at 3:00 p.m. MDT.

About Ceapro Inc.

Ceapro Inc., an innovation-driven biotechnology company, develops and
commercializes organic products for medical, cosmetic, and animal health
industries using proprietary technology and natural, renewable resources.
Based in Edmonton, Alberta, Ceapro is one of Alberta Venture's Fastest Growing
Companies for 2004 and 2005 and is one of Profit Magazine's Next 100
Companies. Ceapro is also the recipient of the ASTech Award for Outstanding
Commercial Achievement for companies with annual sales of less than
$25 million. Ceapro's shares trade on the TSX Venture Exchange under the
symbol CZO. To learn more about Ceapro, log on to our website at
www.ceapro.com. Shares Outstanding: 36,355,950, Recent Close: $0.30.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or the accuracy of this news release.

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the forward-
looking statements contained herein are reasonable, it can give no assurance
that the Company's expectations are correct. All forward-looking statements
are expressly qualified in their entirety by this cautionary statement.
%SEDAR: 00010110E

Ceapro on 6ix

Earlier from Ceapro

Later from Ceapro

All Ceapro news releases